HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A significant shift in the shareholding pattern of pharmaceutical player Corona Remedies Limited took place on June 17, 2026, as major institutional investors moved to acquire substantial stakes. The massive block deal saw marquee names like HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA) entering the fray, signaling strong institutional confidence in the company.
Massive Divestment by Sepia Investments and Anchor Partners
The block deal was primarily driven by the exit of two major sellers. Sepia Investments offloaded 43,28,943 shares of Corona Remedies at a price of ₹1,730 per share, amounting to a deal value of approximately ₹748.9 crore. Adding to this volume, Anchor Partners divested 1,61,861 shares at the same price, contributing another ₹28 crore to the transaction. Combined, these two entities offloaded shares worth roughly ₹776.9 crore in the pharmaceutical company.
HDFC Mutual Fund Dominates the Buy Side
The absorption of these shares was led by a diverse group of twelve institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, acquiring 24,50,000 shares worth approximately ₹423.9 crore. This single transaction accounted for more than half of the total deal value, underscoring HDFC MF's significant conviction in the stock's future prospects.
Other prominent domestic and international players also participated heavily:
- Aditya Birla Sun Life Mutual Fund acquired 4,90,000 shares worth ₹84.8 crore.
- Invesco Mutual Fund picked up 2,89,017 shares, valued at around ₹50 crore.
- Kotak Mahindra Mutual Fund bought 1,61,861 shares, matching the exact quantity sold by Anchor Partners, worth ₹28 crore.
Global Institutional Interest in Corona Remedies
The deal also highlighted significant interest from global fund managers and sovereign wealth funds. Aberdeen Asian Smaller Companies Investment Trust Plc purchased 4,50,868 shares for approximately ₹78 crore, while the Aberdeen Standard Sicav I - Asian Smaller Companies Fund took up 2,74,132 shares worth ₹47.4 crore.
此外，阿布扎比投资局 (ADIA) 通过购买价值 6800 万卢比的 39,130 股股份进入了股权结构表。其他国际参与者包括投资了 2.51 亿卢比的 WhiteOak Capital Mutual Fund，以及购买了价值 2.57 亿卢比股份的 India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund。甚至像 Factory Mutual Insurance Company 这样规模较小的利基参与者也参与其中，购入了价值 1900 万卢比的 10,670 股股份。
核心要点
- 主要机构退出： Sepia Investments 和 Anchor Partners 在 Corona Remedies 的合计持仓退出，总价值约 77.69 亿卢比。
- HDFC MF 领衔买入： HDFC Mutual Fund 是主要的收购方，购入了价值 42.39 亿卢比的股份，占交易总额的 50% 以上。
- 机构信心十足： ADIA 等全球实体以及各类 Aberdeen 基金的参与，表明跨境机构对制药行业有着浓厚的兴趣。